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ABSTRACT
Allogeneic hematopoietic cell transplantation in first complete remission (CR1) is considered the standard of
care, and the only established therapy that offers a possibility of cure for patients with Philadelphia-positive acute
lymphoblastic leukemia (Ph1 ALL). Unfortunately, a number of patients, with suitable HLA-matched donors,
are unable to receive an allograft because they fail to respond, or relapse shortly after induction chemotherapy.
Incorporating imatinib during the induction/consolidation phase is facilitating a higher number of potentially
curative allografts by improving both remission rates and/or the durability of responses in patients with Ph1
ALL. Imatinib and other tyrosine kinase inhibitors are also improving outcomes in elderly patients with Ph1
ALL, ineligible for allografting, when combined with glucocorticoids, and/or conventional chemotherapy.
The addition of imatinib or other tyrosine kinase inhibitors to the therapeutic armamentarium of Ph1 ALL is
reshaping the treatment algorithm and improving prognosis of this dreadful disease.
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Adult patients with Philadelphia chromosome-
positive acute lymphoblastic leukemia (Ph1 ALL)
have an extremely poor prognosis when treated with
conventional chemotherapy alone, yielding a long-
term disease-free survival (DFS) of\10% [1-5]. Allo-
geneic hematopoietic cell transplantation (allo-HCT)
in first complete remission (CR1) is considered the
standard of care, and the only established approach
that offers the possibility of cure in Ph1ALL (Table 1)
[6-14].
The Philadelphia chromosome is among the first
cancer-specific translocations identified in humans
[15]. It is the product of a reciprocal translocation be-
tween the long arms of chromosomes 9 and 22 t(9;22)
(q34;q11), which results in a hybrid BCR-ABL genethat is transcribed into a chimeric BCR-ABL mRNA
[16,17]. Based on the breakpoint of the BCR region,
2 fusion transcripts products are identified: (1) a major
BCR-ABL transcript that encodes the p210 oncopro-
tein, and (2) a minor BCR-ABL transcript that encodes
the p190 oncoprotein, most commonly present in Ph1
ALL. The Philadelphia chromosome is seen in ap-
proximately 20% of cases of adult ALL [18], and up
to 50% in patients above 50 years of age [4]. These on-
coproteins play a key role in the pathogenesis of the
disease by enhancing tyrosine kinase activity, among
others, with a consequent effect on signal transduction
pathways responsible for cellular proliferation [19].
Imatinib mesylate is a selective BCR-ABL tyrosine
kinase inhibitor that is active against Ph1 ALL
[20-23]. Incorporation of imatinib and other tyrosine949
950 Y. R. Abou Mourad et al.Table 1. Selected Studies Evaluating the Outcome of Ph1 ALL after allo-HCT (Pre-imatinib Era)
Authors [Reference] N
Median Age
(Range)
Donor Cell
Source TRM RR Outcome
Goldstone et al. [7] 72 (CR1) — MRD 5 49
MUD 5 23
MRD 5 37%
MUD 5 43%
32% (both groups) OS 5 42% (5-year)
Chao et al. [8] 38 (CR1517) — MRD 5 38 — — 2-year DFS 5 46% in CR1.
2-year DFS 5 28% in .CR1
Dombert et al. [9] 56 (CR1551;
relapsed55)
— MRD 5 44
MUD 5 12
25.4%* 37.2%* OS 5 37% (3-year)
Synder et al. [10] 23 (CR1) 30 (6-44) — 30% 12% DFS 5 65% (3-year)
Stockschlader et al. [11] 10 (CR157) MRD 5 9
MUD 5 1
33% 10% DFS 5 60% at 16.6 months
posttransplant
Barret et al. [12] 67 (CR1533) Age range
5-49 years
MRD 5 67 42%*
40% .CR1
34%*
32% (.CR1)
DFS 5 31% (2-year)
Sierra et al. [13] 18 (CR157) 25 (2-51) MUD 5 18 — 14%* DFS 5 49% (2-year)
Lee et al. [14] 23 (CR1514) 36 (15-44) MRD 5 23 — — DFS 5 43% (2-year)
OS 5 28% (2-year)
TRM indicates treatment-related mortality; RR, relapse rate; CR1, first complete remission; MRD, matched related donor; MUD, matched
unrelated donor; DFS, disease-free survival; OS, overall survival.
*Patients in CR1.kinase inhibitors (TKIs) into the therapeutic arma-
mentarium of Ph1 ALL is reshaping the treatment al-
gorithm of patients with Ph1 ALL. In this article we
provide a comprehensive review of the published
data of imatinib and other TKIs in the setting of
allo-HCT for adult patients with Ph1 ALL. We also
review the role of TKIs in the treatment of elderly pa-
tients with Ph1ALL, not otherwise candidates for
allo-HCT.
Allogeneic HCT after Front-Line Imatinib in Ph1
ALL
Incorporating imatinib during the induction/con-
solidation phase represents a logical approach that
facilitates allo-HCT in a higher number of patients
with Ph1 ALL by improving both remission rates
and/or durability of responses. A prospective phase II
study by Thomas et al. [24] evaluated a combination
of hyper-CVAD (cyclophosphamide, vincristine,
adriamycin, and dexamethasone) plus imatinib 400
mg/day on days 1 through 14 of each chemotherapy
cycle, followed by imatinib-based consolidation/main-
tenance in 20 patients with Ph1 ALL. Fifteen patients
had persistent disease (de novo 5 11; primary induc-
tion failure5 4) and 5 were in CR, after induction che-
motherapy. All 15 (100%) patients treated with
persistent disease achieved CR; but only 10 patients
(de novo5 7, CR5 2, primary refractory5 1, at study
entry) underwent allo-HCT at a median of 3.5 (1-8)
months from starting therapy. Fifteen (75%) of the
20 patients remained alive and in CR at a median fol-
low-up of 20 (4-24) months. Nine of 10 patients
treated with hyper-CVAD plus imatinib, who under-
went allo-HCT, were alive in CR after a median of
12 months. One patient in the allo-HCT group died
in relapse during reinduction. A long-term follow-up
of 54 patients was presented at the annual meeting ofthe American Society of Hematology (ASH) in 2007
[25]; only 16 of 54 patients had undergone allografting
at a median of 5 (1-13) months from start of therapy.
Allo-HCT did not appear to improve 2-year survival
rates when compared to a group of 38 patients who re-
ceived imatinib plus chemotherapy (63% versus 56%)
[25]. However, these results should be interpreted with
caution because of the nonrandomized nature of the
study and the small sample size.
A prospective nonrandomized phase II trial by the
Japan Adult Leukemia Study Group (JALSGALL202)
reported the interim results on 24 patients with newly
diagnosed Ph1 ALL who received imatinib 600 mg/
day in combination with chemotherapy [26]. Imatinib
was prescribed concurrently with induction chemo-
therapy, and alternated with chemotherapy during
consolidation. Allo-HCT was performed if an HLA-
matched donor was available. Twenty-three (96%)
achieved CR after 1 course of remission-induction
chemotherapy plus imatinib. Eighteen (78%) of 23
patients achieved molecular remission (MR). Fifteen
(63%) patients underwent allografting in CR1
(matched-related [MRD] 5 6; matched-unrelated
[MUD] 5 7; cord blood 5 2). At a median follow up
of 1 year, event-free survival (EFS) and overall survival
(OS) rates were reported at 68% and 89%, respec-
tively. This study suggests that imatinib plus chemo-
therapy produces high and durable CR rates,
allowing the necessary time to identify a suitable
HLA-matched donor.
A single institution study by Lee et al. [27] evalu-
ated the efficacy of first-line imatinib and allo-HCT
in 29 adult patients with newly diagnosed Ph1 ALL.
All patients enrolled had completed induction chemo-
therapy and were eligible to proceed with allo-HCT.
Twenty-three of 29 patients, in CR1, received consol-
idation chemotherapy followed by imatinib 400-600
Hematopoietic Cell Allografts for Ph1 ALL and Tyrosine Kinase Inhibitors 951mg/day until allo-HCT. Twenty-two of 23 main-
tained CR until allografting, performed at a median
of 3.5 (2-7) months from starting therapy.When com-
pared to a historic control (chemotherapy without im-
atinib), the group treated with imatinib had lower
relapse rates (4.3% versus 40.7%, P 5 .003). The re-
maining 6 patients, refractory to induction chemother-
apy, received imatinib 600 mg/day plus a combination
of high-dose cytarabine, mitoxantrone, and etoposide.
Three of the 6 patients achieved CR and proceeded to
transplant. Imatinib allowed a higher rate of allograft-
ing than historic approaches (86.2% versus 51.5%, P5
.004). Twenty-eight (CR 5 25; refractory 5 3) of 29
patients underwent HLA-matched sibling (N 5 22)
or unrelated (N 5 6) allo-HCT at a median of 138
(range: 56-217) days from induction therapy. Esti-
mated probability of nonrelapse mortality (NRM) at
3 years was 18.7%. The 3-year estimated probabilities
of both DFS and OS were 78.1% at a median follow-
up of 25 months from allo-HCT. This study suggests
that imatinib is a reasonable and effective postinduc-
tion maintenance therapy which results in sustained
CR that ultimately facilitates allografting.
De Labarthe et al. [28] treated 45 patients with de
novo Ph1 ALL with imatinib in combination with
induction or consolidation chemotherapy. Fourteen
patients (31%) were good early responders after corti-
costeroids and chemotherapy, and continued with
standard induction chemotherapy, without imatinib,
until achieving hematologic CR. Patients were subse-
quently treated with imatinib 600 mg/day plus consol-
idation chemotherapy until allo-HCT for a planned
period of 90 days. Another cohort of 31 (69%) poor
early responders were treated with imatinib 800 mg/
day in combination with vincristine and dexametha-
zone (DIV), and imatinib was continued at the same
dose until allo-HCT for a planned period of 90 days.
Simultaneous administration of imatinib and chemo-
therapy was well tolerated. The overall CR rate was
96%, with 2 deaths occurring in the DIV group. Over-
all, the authors reported a BCR-ABL PCR negativity
rate of 29%. In addition, 56% of patients achieved
low PCR levels (defined as a BCR-ABL/ABL ratio
between 1025 and 1024). Twenty-two (good early re-
sponder5 8; poor early responder5 14) of 39 patients
in CR proceeded to allografting once a suitable HLA-
matched donor was available (MRD5 15; MUD5 7),
at a median of 92 (18-159) days from induction chemo-
therapy. Fourteen of 22 patients had achieved low
PCR levels prior to allo-HCT. At 18 months, esti-
mated cumulative incidence of relapse, DFS, and OS
for allograft recipients were reported at 30%, 51%,
and 65%, respectively. This study shows that combin-
ing imatinib and chemotherapy is a reasonable pre-
allo-HCT strategy.
A prospective multicenter trial byWassmann et al.
[29] evaluated 2 different schedules of imatinib in 92patients with Ph1 ALL who received uniform induc-
tion and consolidation chemotherapy. Forty-seven
patients (cohort I) received imatinib alternating with
chemotherapy, whereas 45 patients (cohort II) re-
ceived imatinib concomitantly with chemotherapy un-
til allo-HCT. Patients in cohort I received imatinib
400 mg/day. Twelve patients had the dose increased
to 600 mg/day. Patients in cohort II received imatinib
at 600 mg/day. A higher proportion of patients in co-
hort I had chemoresistant disease. PCR-negativity was
superior in patients in cohort II (52% versus 19%); but
grade III-IV cytopenias and transient hepatotoxicity,
requiring treatment disruption, were also higher in
this cohort (87% versus 53%). Seventy-seven percent
of patients from each cohort proceeded to allo-HCT
in CR1. Median survival of patients in cohorts I and
II were 16.3 months and 19.6 months, respectively.
The estimated 1-year and 2-year probability of sur-
vival, after diagnosis, for patients in cohort I were
72% and 36.2%, and in cohort II 61% and 43%,
respectively (P 5 .97). This study shows that both
schedules of imatinib facilitate allo-HCT in CR1 in
a significant proportion of patients; but concurrent
administration of imatinib and chemotherapy, albeit
not statistically significant, appears to offer a better
antileukemia effect.
The UKALLXII/ECOG2993 study originally
intended to evaluate a preparative regimen of total
body irradiation (TBI) and etoposide in 267 patients
with Ph1 ALL in the pre-imatinib era [30]. Imati-
nib 600 mg/day was added following induction che-
motherapy and for 2 years or until relapse/
progression postallograft to a subsequent group of
153 patients (following first induction 5 89; imati-
nib started with second induction 5 64). The au-
thors conclude that addition of imatinib during
induction may result in higher CR rates, but did
not appear to improve survival [30]. These studies
are summarized in Table 2.
Imatinib Facilitates allo-HCT in Patients with
Relapsed or Refractory Ph1 ALL
Achieving a CR before initiation of the myeloabla-
tive preparative chemotherapy (or chemoradiother-
apy) is a determinant for improved outcomes
in patients with Ph1 ALL after allografting [31].
Wassmann et al. [23] evaluated the efficacy of imatinib
as a salvage strategy in 46 patients, median age of 43.5
(17-57) years, with relapsed or refractory Ph1 ALL
who had not received a previous transplant. Imatinib
was administered at 600 mg/day. Ten patients
achieved CR (hematologic or bone marrow) prior to
proceeding with allo-HCT. Twenty-two (73%) of 30
eligible patients underwent allo-HCT, and 18 (82%)
attained CR, 1 patient had refractory disease, and 3
died prior to response assessment. Seven (32%)
952 Y. R. Abou Mourad et al.Table 2. Selected Trials of Imatinib Up-front with Induction/Consolidation in Patients with Ph1 ALL Prior to Allogeneic HCT
Author [Reference] N (allo-HCT)
Median Age
(Range) Years Regimen CHR (Mol. R)
Median
(Range) Months
to allo-HCT DFS/OS
Thomas et al. [24] 20 (allo-HCT 5 10) 42 (19-75)
35 (17-57) for
the allo
group
Hyper-CVAD
concurrent cwith
imatinib 400 mg
daily
100% (75%) 3.5 (1-8) Allo-HCT 9/10 alive
in CR (median F/U
12 months)
Imatinib-chemo
6/10 alive in CR
(median F/U 20
months).
Thomas et al. [25] 54 (allo-HCT 5 16) 51 (17-48) Hyper-CVAD
concurrent with
imatinib 400-800
mg/day
93% (52%) 5 (1-13) 2-year OS 5 63%*
Towatari et al. [26] 24 (allo-HCT 5 15)
MUD 5 7
MRD 5 6
CB 5 2
41.5 (15-59) Imatinib 600
mg/day†
96% (78%) — 1-year EFS 5 68%
1-year OS 5 89%
Lee et al. [27] 29 (allo-HCT 5 28)
MRD 5 22
MUD 5 6
36 (18-55) Hyper-CVAD-based
with imatinib
400-600 mg/day
50% (for
refractory
group 5 6)
86.2% for all
patients
3.5 (2-7) DFS/OS 5 78.1%
(estimated 3-year)
at median F/U of
25 months
de Labarthe
et al. [28]
45 (allo-HCT 5 22)
MRD 5 15
MUD 5 7
45 (16-59) Imatinib 600-800
mg/day daily‡
96% (56%)
PCR
negativity 29%
3 (0.6-5.5) DFS 5 51%
OS 5 65% (At
18 months)
Wassmann
et al. [29]
47 (allo-HCT 5 36)
alternating
46 (21-65) Imatinib 400-600
mg/day after
second induction
— (before first
consolidation 5
19%)
5 (3.5-13) Median survival
16.3 months
1-year OS 5 72%
2-year OS 5 36%
45 (allo-HCT 5 35)
concurrent
41 (19-63) Imatinib 600 mg/day
concurrent after
first induction
95% (before first
consolidation 5
52%)
5 (3-6.5) Median survival
19.6 months
1-year OS 5 61%
2-year OS 5 43%
Fielding et al. [30] Pre-imatinib 5267 40 (15–60) No imatinib 83% 3-year OS 5 26%
(no imatinib)Post-imatinib 5 153 42 (16–64) Imatinib 600 mg/day
After first
induction 5 89
91% 3-year OS 5 23%
(imatinib-treated
group)Started with second
induction 5 64
81%
CHR indicates complete hematologic response; Mol. R, molecular response; DFS, disease-free survival; OS, overall survival; MUD, matched
unrelated donor; MRD, matched related donor; CB, cord blood; EFS, event-free survival.
*With allo-HCT compared to 56% without allo-HCT.
†Concurrent with induction and alternating with consolidation.
‡With induction in poor early responders or alternating with consolidation in good early responders.maintained a CR after a median follow-up of 9.4 (1.7-
23.8) months, whereas 7 (32%) relapsed after a median
of 5.2 months post-allografting. Treatment-related
mortality (TRM) was 36%. Estimates of 1-year DFS
and OS for all patients were 25.5% and 44.8%, respec-
tively. The probability of 1-year DFS was superior
when allo-HCT was performed in CR compared to
persistent (relapsed or refractory) disease (51.4% ver-
sus 8.3%, P 5 .006). This study shows that imatinib
is effective salvage therapy prior to allo-HCT in pa-
tients with Ph1 ALL; but allo-HCT must be per-
formed promptly before disease progression ensues.
Also, it confirms that remission status at time of allo-
HCT is an important determinant of outcome. Thisand other studies using TKIs in a similar manner are
summarized in Table 3 [20,23,32,33].
Prophylactic Administration of Imatinib
Post-allo-HCT
Carpenter et al. [34] provided safety data on post-
allografting imatinib therapy in 15 high-risk Ph1ALL
patients (children and adults). Adults were given imati-
nib at a dose of 400 mg/day after hematologic engraft-
ment until 1 year from allo-HCT [34]. Fourteen
patients had received imatinib prior to allo-HCT.
Grade I-III nonhematologic toxicities were reported
in 66.6%. Administering imatinib early after allograft-
ing is feasible; however, efficacy of this approach and
Hematopoietic Cell Allografts for Ph1 ALL and Tyrosine Kinase Inhibitors 953Table 3. Selected Studies Evaluating Imatinib in Relapsed or Refractory Ph1 ALL
Authors [Reference] N
Median Age
(Range) Years Imtinib Dose/Day Responses Outcome
Ottman et al. [20] 48 (post-allo-
HCT 5 21%)
50 (22-78) 400-600 mg CHR 5 19%
CMR 5 10%
PMR 5 31%
Median TTP 5 2.2
months
Median OS 5 4.9
months
OS 5 40% (at 6 months)
Wassmann et al. [23] 46* 43.5 (17-57) 600 mg — 1-year DFS 5 25%†
1-year OS 5 44.8%
Wassmann et al. [32] 68 (post-allo-
HCT 5 29%)
48 (17-76) 400-600 mg CHR 5 30%
CMR 5 29%
PMR 5 11%
PFS 5 23%
(at 6 months)
OS5 33% (at 12 month)
OS5 23% (at 18 month)
Druker et al. [33] 58 (Ph1 ALL 5 10
LyBC 5 10
MyBC 5 38)
48 (24-76) 300-1000 mg ORR 5 70%‡
CHR 5 20%
MR 5 50%
RR 5 85% at a median
of 58 (42-123) days
after starting imatinib
CHR indicates complete hematologic response; CMR, complete marrow response; PMR, partial marrow response; TTP, time to progression;
OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; LyBC, CML-lymphoid blast crisis; MyBC, CML-myeloid
blast crisis; MR, marrow response; RR, relapse rate.
*Four in CR1, 2 in .CR1, 16 (73%) refractory, none had an allo-HCT.
†Fifty-one percent when allo-HCT was performed in CR versus 8.3% for overt leukemia (P 5 .006).
‡Overall response rate for ALL and LyBC.its ultimate effect on minimal residual disease (MRD)
post allo-HCT is not known.
Imatinib plus Donor Lymphocyte Infusion (DLI)
Patients with Ph1 ALL relapsing after allo-HCT
have a poor prognosis. There is anecdotal experience
using imatinib in combination with DLI in patients
with Ph1 ALL relapsing after an allograft. Shimoni
et al. [22] reported on 2 patients with relapsed Ph1
ALL, after allo-HCT, where imatinib induced hema-
tologic CR and BCR-ABL negativity (by FISH) prior
to administering DLI of 1 108 CD31 cells/kg within
2 weeks from imatinib [22]. Acute graft-versus-host
disease (aGVHD) occurred 2 weeks following DLI
in both cases. One patient who received imatinibmain-
tenance after DLI remained alive in CR at 4.5 months,
whereas the second patient died of relapsed disease 4
months after DLI.
Wassmann et al. reported a series of 5 patients re-
ceiving DLI for relapsed Ph1 ALL either prior to im-
atinib (N 5 1), concomitantly with imatinib (N 5 1),
or following imatinib (N 5 3) [35]. Administration
of imatinib was feasible but did not appear to offer
a survival benefit because all patients eventually re-
lapsed. Using imatinib before DLI is feasible; how-
ever, larger clinical trials are needed to determine the
precise benefit of imatinib in this setting.
MRD Post-allo-HCT: Is There a Role for Imatinib?
One-third of patients with Ph1 ALL transplanted
in CR1 ultimately relapse and die from their disease
[20]. Persistence of molecular disease after allo-HCT
predicts for a higher risk of relapse [36]. A prospectivestudy by Wassmann et al. [35] assessed the efficacy of
imatinib 400 mg/day in 27 patients with Ph1 ALL
with evidence of persistent molecular disease after
allo-HCT (N 5 24) or auto-HCT (N 5 3). BCR-
ABL became undetectable in 52% of these patients
after a median of 1.5 (0.9-3.7) months; and MR were
sustained while on imatinib treatment. However, 3 pa-
tients relapsed after discontinuation of imatinib. Inter-
estingly, 12 (92%) of 13 patients who failed to achieve
PCR negativity, within 2 to 3 months after starting
imatinib, relapsed at a median of 3 months.
Other Tyrosine Kinase Inhibitors
Dasatinib. Dasatinib (N-(2-chloro-6-methylphenyl)-2
[6-[4-(2-hydroxylethyl)-1-piperazinyl]-2-methyl-4-pyri-
madinlyl]amino]-5-thiazolecarboxamide, monohydrate)
is a multityrosine kinase inhibitor that targets BCR-
ABL, various SRC family of kinases (FYN, LCK,
SRC, and YES), c-KIT, EPHA2, and platelet-derived
growth factor receptor-b (PDGFR-b) at very low con-
centrations [37-39]. It is approved by the United States
Food and Drug Administration (U.S. FDA) for pa-
tients with chronic myelogenous leukemia (CML)
and Ph1 ALL resistant or intolerant to imatinib
[40]. Dasatinib differs from imatinib by its ability to
bind to both the active and inactive conformations of
the ABL kinase domain [41].
A phase II opened-label multicenter international
trial (START-L) evaluated the efficacy and safety of
dasatinib 70 mg twice daily in patients with Ph1
ALL who were imatinib-resistant or imatinib-intoler-
ant [42]. A total of 36 patients (imatinib-resistant5 34;
imatinib-intolerant5 2 patients) were evaluated. Over
954 Y. R. Abou Mourad et al.50% of patients had received imatinib for over a year,
and 15 (42%) had failed a prior HCT. Hematologic
toxicities, including neutropenia (72%), anemia
(47%), and thrombocytopenia (78%), ocurred in a ma-
jority of these patients. Grade III-IV nonhematologic
toxicities consisted of febrile neutropenia (11%), diar-
rhea (8%), asthenia (8%), and pleural effusions (3%),
among others. Overall hematologic response was
50%; major hematologic response (MaHR) were re-
ported in 15 (42%) of 36 patients at a median of 1.8
months. Ten (67%) patients with an MaHR did not
progress after 8 months of follow-up. Major cytoge-
netic responses were reported in 21 (58%) patients.
The authors conclude that dasatinib is effective in pa-
tients with imatinib-resistant or imatinib-intolerant
Ph1 ALL. A 2-year follow-up of the START-L, up-
dated at ASH 2007, showed a median OS of 8.0
months and 1-year progression-free survival (PFS) of
22% after dasatinib initiation [43]. Dasatinib is capable
of inducing hematologic and cytogenetic responses on
most mutational genotypes of BCR-ABL except
T315I [41,42,44,45].
Feasibility of dasatinib as induction therapy.
Ravandi et al. [46] reported results of a phase II trial for
patients with newly diagnosed or relapsed Ph1 ALL or
LY-BP CML who received dasatinib 50 mg twice daily
for the first 14 days of each of 8 cycles of alternating hy-
per-CVAD and high-dose cytarabine and methotrexate
(MTX). Patients achieving CR continued to receive
maintenance dasatinib 50 mg twice daily, and vincristine
andprednisone everymonth for 2 years followedby dasa-
tinib treatment indefinitely. Outcomes were evaluated in
different cohorts of patients: cohort I included 15 previ-
ously untreated Ph1 ALL patients with a median age
of 55 (23-79) years; and cohort II included 4 patients
with relapsed Ph1 ALL or LY-BP CML with a median
age of 43 (26-69) years. Patients in both cohorts had re-
ceived a median of 4 (1-8) cycles. At the time the authors
presented at ASH 2007, 14 patients in cohort I and 3 pa-
tients in cohort II were evaluable for response to induc-
tion therapy. Thirteen (93%) patients in cohort I and 3
(100%) patients in cohort II achieved CR after 1 treat-
ment cycle. Ten (91%) of 11 patients in cohort I and 3
(75%) of 4 patients in cohort II achieved cytogenetic
CRafter 1 cycle. Six patients achieved completeMRafter
the first cycle.Median time to neutrophil and platelet re-
coverywas 18 and25days, respectively, for patients in co-
hort I, and 19 and 31 days, respectively, for patients in
cohort II. Grade III-IV toxicity consisted of 7 episodes
of GI bleeding as well as infections, diarrhea, hypophos-
phatemia, hypocalcemia, andelevated liver enzymes.One
(7%)patient incohort Idied frominfections.Theauthors
conclude that dasatinib is feasible to administer in combi-
nation with hyper-CVAD, and could result in early MR
in Ph1 ALL and LY-BP CML; but none of the patients
had received an allo-HCT when the study was reported
[46].Nilotinib. Nilotinib is an aminopyrimidine-deriva-
tive TKI that is active against imatinib-resistant CML
and is more potent, in vitro, than imatinib [44,47,48].
In 2007, the U.S. FDA granted accelerated approval
to nilotinib for the treatment of chronic and acceler-
ated phase CML in adult patients resistant or intoler-
ant to prior therapy that included imatinib. Nilotinib,
similar to imatinib, can only bind the inactive confor-
mation of the ABL kinase domain, but with a 25-fold
greater affinity that imatinib. A phase I dose escalation
study by Kantarjian et al. [49] evaluated nilotinib in
119 patients with imatinib-resistant CML or Ph1
ALL. Thirteen patients with Ph1 ALL (hematologic
relapse 5 10; persistent molecular disease 5 3) were
included in the study. Only 1 (10%) of 10 patients
with hematologic relapse achieved a partial hemato-
logic response and 1 of 3 patients with persistent mo-
lecular disease achieved a complete MR. These
findings suggest that nilotinib may have a role in
Ph1 ALL; however, the nature of the study design
(ie, phase I) and the small sample size limit the ability
to draw conclusions about its efficacy in Ph1 ALL.
A phase II opened-label study evaluated the safety
and efficacy of nilotinib in 41 patients, median age of
46 (18-75) years, with relapsed (N 5 38) or refractory
(N5 3) Ph1ALL [50]. Nilotinib was administered for
a median of 53 (1-563) days and a median dose of 800
mg/day. Responses were as follow: CHR 5 24%; he-
matologic improvement 5 2%; stable disease (SD) 5
22%; progressive disease (PD) 5 34%. The authors
suggest that nilotinib appears to be active in patients
with relapsed or refractory Ph1 ALL and propose
future trials combining nilotinib with conventional
chemotherapy.
Hematologic toxicicties are commonly seen with
the various TKIs discussed herein. Nonhematologic
toxicities including fluid retention and gastrointestinal
side effects, among others, are common with TKIs.
However, pleural effusions appear to be more com-
monly seen with dasatinib (grade I-IV 5 19% [7/36
patients]; grade III-IV 5 3% [1/36 patients] when us-
ing a dose of 70 mg twice daily) [43], whereas elevation
of serum lipase (grade III-IV 5 28% [9/32 patients]
when using a dose of 400 mg twice daily) [50] and
elevation of unconjugated bilirubin (grade I-I 5 19%
[6/32 patients] and grade III-IV 5 9% [3/32 patients]
when using a dose of 400 mg twice daily) [49] are more
commonly seen with nilotinib.
TKIs in Elderly Patients with Ph1 ALL Not
Candidates for allo-HCT
The incidence of Ph1 ALL increases with age,
achieving 50% in patients older than 50 years [4,51].
Elderly patients with Ph1 ALL have a poor prognosis
because of low CR rates, short remissions, and high
TRM. Imatinib and dasatinib have been evaluated, as
Hematopoietic Cell Allografts for Ph1 ALL and Tyrosine Kinase Inhibitors 955monotherapy or in combination with chemotherapy,
in older patients with Ph1 ALL.
TKI in Patients Older Than 55 Years of Age
Imatinib monotherapy. Ottmann et al. [52] pro-
spectively compared imatinib (N5 28) to age-adapted
multiagent chemotherapy (N5 27) in patients over 55
years of age with Ph1 ALL ineligible for allo-HCT.
The median ages for patients randomized to receive
either imatinib or multiagent chemotherapy were 66
(54-79) years or 68 (58-78) years, respectively. Imatinib
600 mg/day was administered in 4-week cycles. Cross-
over was permitted if there was no reduction of blasts
after 2 weeks of assigned treatment. CNS prophylaxis
was identical in all patients. Responses to induction
were superiorwith imatinib (overallCR [CRwith recov-
ery of peripheral blood counts 1 CRi, CR without
complete recovery of peripheral blood counts] 5
96.3% versus 50%, P5 .0001) (Table 4). Also, imatinib
was associated with a significantly lower incidence of
nonhematologic severe adverse events, both in the num-
ber of patients (39%versus 86%,P5 .005) or numberof
serious adverse events (N 5 12 versus N 5 46, P 5
.0001). The estimated 2-year OS for all patients was
42% (68%), with no significant difference between
the 2 groups.The authors conclude that imatinib results
in significantly higher CR rates in elderly patients withTable 4. Selected Trials of Tyrosine Kinase Inhibitors in Elderly Patients wide novoPh1ALLwith low toxicity compared to induc-
tion chemotherapy.
Imatinib plus steroids for elderly patients with
Ph1 ALL. The Group for Research on Adult Acute
Lymphocytic Leukemia (GRAALL) evaluated imati-
nib 600 mg/day plus methylprednisolone alternating
with chemotherapy in 30 patients, 55 years or older,
with previously untreated Ph1 ALL (GRAALL
AFR09) [53]. All patients were treated with methyl-
prednisolone for 7 days, followed by chemotherapy-
based induction and subsequent consolidation with
imatinib and glucocorticoids for 2 months. Patients
in CR, after consolidation, received 10 cycles of alter-
nating chemotherapy, including 2 additional 2-month
cycles of imatinib. Twenty-one (72%) of 29 evaluable
patients achieved CR after induction therapy, and
5 additional patients achieved CRs after salvage with
imatinib. The 1-year relapse-free survival (RFS) and
OS were 58% and 66%, respectively. The authors
compared these results to a historic cohort of 21 pa-
tients, who did not receive imatinib, demonstrating
better CR rates (72% versus 29%, P 5 .003), 1-year
RFS (58% versus 11%, P 5 .0003), and 1-year OS
(66% versus 43%, P5 .005) with imatinib. These find-
ings albeit encouraging are limited by the relatively
small sample size; there are also several unanswered
questions including long-term outcomes beyond
1 year and the optimal dose and duration of imatinibth Ph1 ALL Not Candidates for Allogeneic HCTStudy [Ref] Study Type
Median Age
(Range) Years
Imatinib/dasatinib
Dose N CHR DFS/OS
Ottman
et al. [53]
Randomized
(imatinib versus
multiagent
chemotherapy)
Imatinib arm 5 66
(54-79)
Multiagent
chemotherapy5
68 (58-78)
Imatinib 600
mg/day
Imatinib 5 28
Multiagent
chemotherapy5 27
Imatinib 5 96.3%
versus
multiagent
chemotherapy 5
50%
P5 .0001
OS 5 42%
(estimated
2-year)
Delannoy et al.
GRAALL
AFR09 [54]
Historical control Imatinib-
containing 5
65.8 (58-78)
Historic 5 61.3
(56.1-67.1)
Imatinib 600
mg/day
Imatinib-
containing 5 30
Historic 5 21
Imatinib-
containing 5 72%
Historic 5 29%
P5 .003
1-year RFS
Imatinib-contating
5 58% versus
Historic 511%,
(P 5 .0003)
1-year-OS Imatinib-
containing 5 66%
vs. Historic 5
43%,
P 5 .005)
Vignetti,
et al. [56]
Single arm 69 (61-83) Imatinib 800
mg/day and
prednisone
40 mg/m2
30 100%* OS 5 74% (1-year
probability)
DFS 5 48% (1-year
probability)
Foa et al. [57] Single arm† 57 (30-74) Dasatinib 70 mg
twice daily and
prednisone up
to 60 mg/m2
23 100%‡ —
CHR indicates complete hematologic responses; DFS, disease-free survival; OS, overall survival. RFS, relapse-free survival.
*Only 29 patients were eligible.
†Interim analysis.
‡At day 22 posttreatment.
956 Y. R. Abou Mourad et al.therapy needed. Improvement in outcome of elderly
patients with Ph1ALL after introduction of imantinib
has been reported by other groups [54].
The Gruppo Italiano Malattie Ematologiche del-
l’Adulto (GIMEMA) evaluated a chemotherapy-free
regimen (LAL0201-B protocol) that combined imati-
nib 800 mg/day preceded by increasing doses of pred-
nisone (10-40 mg/m2/day) for 7 days and additional
prednisone (40 mg/m2/day) for 45 days, in 30 patients,
median age of 69 (61-83) years, with Ph1 ALL [55].
Seven (23%) required dose reduction or temporary
discontinuation of imatinib because of nonhemato-
logic toxicity. A CHR was reported in all 29 (100%)
evaluable patients, and a complete MR in 1 (3%)
patient. The median survival and the median duration
of hematologic responses in 29 patients were 20
months and 8 months, respectively. Thirteen (45%)
patients were alive and in continuous remission at
a median of 10 (1-32) months; 14 (48%) patients re-
lapsed after amedian of 4 (3-28) months, and 2 patients
died in CR at 5 and 15 months. The 1-year probability
of OS and DFS was 74% and 48%, respectively. This
study supports a role for imatinib in combination with
prednisone; but whether additional benefit could be
derived from a longer maintenance remains unknown.
Dasatinib plus prednisone as front-line therapy
in elderly Ph1 ALL. The GIMEMA group pre-
sented their first interim analysis of LAL1205, which
evaluates the safety and efficacy of dasatinib and pred-
nisone as induction treatment in 23 patients, median
age of 57 (30-74) years, with Ph1 ALL [56]. The reg-
imen consisted of dasatinib 70 mg twice daily and
prednisone up to 60 mg/m2/day started 1 week prior
to dasatinib and continued until day 31. Intrathecal
MTX infusions were administered on days 22 and
43. Dasatinib was administered for a total of 84 days.
CHR was 100% after 3 weeks. This interim analysis
suggests that the combination of dasatinib plus predni-
sone is well tolerated and capable of inducing rapid and
impressive hematologic responses. A longer follow-up
is needed to determine durability of reponses and,
more important, the impact of dasatinib on OS. This
and other studies are summarized in Table 4.
SUMMARY
Imatinib and other TKIs are becoming an integral
component of modern treatment algorithms for pa-
tients across different stages of Ph1 ALL. Aforemen-
tioned studies show that incorporation of imatinib as
a pretransplant strategy facilitates a higher rate of
allo-HCT by improving both quality and durability
of responses prior to allografting without significant
increase in toxicity. Using imatinib early during induc-
tion, and continuing through consolidation, results in
higher and durable CR rates. Achieving CR, moreoveranMR, at the time of allo-HCThas a beneficial impact
on outcomes.
Imatinib is also a reasonable and promising strat-
egy in the posttransplant setting to consolidate and
maintain molecular responses that may ultimately im-
prove survival for patients with Ph1 ALL. Available
data shows that imatinib is relatively well tolerated in
this setting. However, the optimal duration of therapy
posttransplant, particularly in patients with sustained
MR remains to be determined.
Newer generation of TKIs such as dasatinib,
among others, are already showing encouraging re-
sponses in patients with relapsed Ph1ALL after trans-
plantation. Decisions as to which TKI is better in this
setting will require large randomized, multicenter
trials.
Combining imatinib with conventional chemo-
therapy is feasible and results in better EFS and OS
compared to historic controls of adult patients with
newly diagnosed Ph1 ALL treated with conventional
chemotherapy alone, albeit the follow-up is relatively
short [24,57]. Nevertheless, in the absence of large
prospective randomized trials comparing imatinib-
chemotherapy regimens versus allo-HCT as a consoli-
dative strategy, allo-HCT remains the best therapeutic
approach that offers a possibility of cure in Ph1 ALL.
Imatinib or other TKIs are also improving out-
comes in elderly patients with Ph1 ALL, ineligible
for allografting, when combined with glucocorticoids,
with or without chemotherapy. Future clinical trials
should continue to evaluate the optimal way of com-
bining imatinib with conventional chemotherapy in
patients unable to tolerate allografting and to deter-
mine the optimal duration of therapy once a MR has
been obtained. TKIs are improving the overall prog-
nosis of Ph1 ALL.
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